CLINICAL TRIALS PROFILE FOR NYSTATIN
✉ Email this page to a colleague
All Clinical Trials for NYSTATIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00001812 ↗ | A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2 | Completed | National Cancer Institute (NCI) | Phase 3 | 1999-04-01 | In patients who are receiving intravenous high dose Interleukin-2, patients will be randomized into two groups: group one will receive nystatin swish and swallow immediately before initiation of IL-2, and the second group will receive a placebo. The patients in each group will be monitored and evaluated for differences in the rate and severity of development of oral irritation during treatment. They will also be studied for differences between the two groups in the number of doses of IL-2 taken. |
| NCT00001998 ↗ | Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC) | Completed | Argus Pharmaceuticals | N/A | 1969-12-31 | To define the pharmacokinetic characteristics of Nystatin LF IV (intravenous) in human subjects with AIDS-related complex (ARC) after administration of a single IV dose at each of 4 dose levels. |
| NCT00002057 ↗ | Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC | Completed | Bristol-Myers Squibb | N/A | 1969-12-31 | To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prevention of oral candidiasis in patients with AIDS or AIDS related complex (ARC) (group III or IV, CDC classification). |
| NCT00002097 ↗ | A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection. | Completed | Argus Pharmaceuticals | Phase 1 | 1969-12-31 | To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and clinical pharmacology of intravenous nystatin. |
| NCT00002112 ↗ | Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome | Completed | Pfizer | N/A | 1969-12-31 | To compare the efficacy, safety, and toleration of fluconazole as a single daily oral suspension for 14 days versus nystatin oral suspension 4 times daily for 14 days in the treatment of oropharyngeal candidiasis in patients with AIDS or HIV infection. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NYSTATIN
Condition Name
Clinical Trial Locations for NYSTATIN
Trials by Country
Clinical Trial Progress for NYSTATIN
Clinical Trial Phase
Clinical Trial Sponsors for NYSTATIN
Sponsor Name
